Pfizer Inc. (PFE) Lowered to Buy at Vetr Inc.
Pfizer Inc. (NYSE:PFE) was downgraded by stock analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report issued on Thursday. They currently have a $36.36 target price on the biopharmaceutical company’s stock. Vetr‘s price objective indicates a potential upside of 10.99% from the company’s current price.
PFE has been the topic of several other reports. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Jefferies Group lowered their price objective on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, September 13th. Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a research report on Monday, August 22nd. Finally, Argus reissued a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Tuesday, October 4th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Pfizer presently has an average rating of “Buy” and a consensus target price of $38.59.
Pfizer (NYSE:PFE) traded down 0.94% during trading on Thursday, hitting $32.76. The stock had a trading volume of 24,182,290 shares. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market cap of $198.71 billion, a price-to-earnings ratio of 29.04 and a beta of 0.86. The firm has a 50 day moving average of $34.08 and a 200-day moving average of $34.25.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/pfizer-inc-pfe-lowered-to-buy-at-vetr-inc.html
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period last year, the business earned $0.56 EPS. Pfizer’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities analysts predict that Pfizer will post $2.46 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.66%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.
Institutional investors have recently modified their holdings of the company. Nelson Roberts Investment Advisors LLC increased its stake in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares in the last quarter. Stelac Advisory Services LLC acquired a new stake in Pfizer during the second quarter valued at about $110,000. Tuttle Tactical Management LLC acquired a new stake in Pfizer during the second quarter valued at about $117,000. Delphi Private Advisors LLC increased its stake in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares in the last quarter. Finally, Commonwealth Financial Services LLC increased its stake in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares in the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.